Roth Capital Weighs In On 5 Biotech Stocks To Watch

By Sarah Roden

As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with definitive catalysts.” Though the analyst rates 15 biotech stocks, we have highlighted 5 of them.

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Pantginis highlighted CLDX as one of his “focus picks,” maintaining a Buy rating on the stock with a price target of $43. Pantginis notes that CLDX “remains a leader in the immunotherapy space.” The analyst sees a lot of promise in Rintega, a cancer vaccine which he believes will become the second cancer vaccine to earn U.S. approval. The analyst adds that Celldex’s achievements have been “major contributors to the gradual change of perception with regard to cancer vaccines.” In addition, CLDX is conducting studies on treatments for solid tumors, ovarian cancer, and breast cancer, which Pantginis believes will increase visibility for Celldex.

Pantginis has rated Celldex 9 times since July 2013, earning an 89% success rate recommending the stock with a +53.4% average return per recommendation.

On average, the top analyst consensus for Celldex on TipRanks is Strong Buy.

 Biotech CLDX

BioLineRx Ltd. (NASDAQ: BLRX)

Pantginis maintained a Buy rating on BLRX with a price target of $10.50. Pantginis notes that BLRX has “established itself during 2014 as a company that not only delivers on its clinical development milestones but also executes on the business development front.”  The analyst says the stock “offers an appealing value proposition with multiple milestones expected in 2015” due to three main therapies in its pipeline which target AML, celiac disease, and AMI. Pantginis expects a slew of milestones throughout the end of 2016, from study initiations to study completions.

Pantginis has rated BioLineRx 13 times since July 2014, earning an 84% success rate recommending the stock and a +21.7% average return per recommendation.

1 2 3
View single page >> |

Disclosure: None


How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.